3,4-dihydroxyphenylglycolaldehyde profile

3,4-dihydroxymandelaldehyde : A hydroxyaldehyde consisting of phenylacetaldehyde having three hydroxy substituents located at the alpha-, 3- and 4-positions. It is a metabolite of noradrenaline. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	151725
CHEBI ID	27852
SCHEMBL ID	1332823
MeSH ID	M0050631

Synonym
3,4-dihydroxyphenylglycolaldehyde
13023-73-9
C05577
3,4-dihydroxymandelaldehyde
benzeneacetaldehyde, alpha,3,4-trihydroxy-
2-(3,4-dihydroxyphenyl)-2-hydroxyacetaldehyde
alpha,3,4-trihydroxyphenylacetaldehyde
CHEBI:27852
3,4-dihydroxyphenylglycolic aldehyde
alpha,3,4-trihydroxybenzeneacetaldehyde
SCHEMBL1332823
alpha,3,4-trihydroxy-benzeneacetaldehyde
a,3,4-trihydroxy-benzeneacetaldehyde
2-(3,4-dihydroxyphenyl)-2-hydroxy-acetaldehyde
2-(3,4-dihydrox-yphenyl)-2-hydroxyacetaldehyde
Q27103374
DTXSID30897223

Role	Description
neurotoxin	A poison that interferes with the functions of the nervous system.
mouse metabolite	Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
human metabolite	Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
catechols	Any compound containing an o-diphenol component.
hydroxyaldehyde
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Neuronal System	166	50
Transmission across Chemical Synapses	122	50
Neurotransmitter release cycle	31	33
Norepinephrine Neurotransmitter Release Cycle	12	12
Tyrosine Metabolism	16	57
Alkaptonuria	16	57
Hawkinsinuria	16	57
Tyrosinemia Type I	16	57
Disulfiram Action Pathway	23	66
Tyrosinemia, Transient, of the Newborn	16	57
Dopamine beta-Hydroxylase Deficiency	16	57
Monoamine Oxidase-A Deficiency (MAO-A)	16	57
Tyrosine metabolism ( Tyrosine metabolism )	28	41
NAD+ + 3,4-Dihydroxy-mandelaldehyde + H2O = NADH + 3,4-Dihydroxy-mandelic acid ( Tyrosine metabolism )	4	5
NAD+ + 3,4-Dihydroxy-phenyl-ethyleneglycol = NADH + 3,4-Dihydroxy-mandelaldehyde ( Tyrosine metabolism )	8	4
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-2	0	490

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (7.14)	18.7374
1990's	6 (42.86)	18.2507
2000's	5 (35.71)	29.6817
2010's	1 (7.14)	24.3611
2020's	1 (7.14)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (14.29%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	12 (85.71%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
3,4-dihydroxyphenylacetic acid 3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.. (3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.. dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.	4.89	6	catechols; dihydroxyphenylacetic acid	human metabolite
3,4-dihydroxyphenylacetaldehyde 3,4-dihydroxyphenylacetaldehyde : A phenylacetaldehyde in which the 3 and 4 positions of the phenyl group are substituted by hydroxy groups.	4.89	6	alpha-CH2-containing aldehyde; catechols; phenylacetaldehydes	Escherichia coli metabolite; human metabolite; mouse metabolite
hydroxyl radical Hydroxyl Radical: The univalent radical OH. Hydroxyl radical is a potent oxidizing agent.	2.41	2	oxygen hydride; oxygen radical; reactive oxygen species
carnosine polaprezinc: stimulates bone growth	2.21	1	amino acid zwitterion; dipeptide	anticonvulsant; antineoplastic agent; antioxidant; Daphnia magna metabolite; geroprotector; human metabolite; mouse metabolite; neuroprotective agent
4-hydroxy-2-nonenal 4-hydroxy-2-nonenal: cytotoxic product from peroxidation of liver microsomal lipids; RN given refers to cpd without isomeric designation. 4-hydroxynon-2-enal : An enal consisting of non-2-ene having an oxo group at the 1-position and a hydroxy group at the 4-position.. 4-hydroxynonenal : A monounsaturated fatty aldehyde that is nonanal that has undergone dehydrogenation to introduce a double bond at any position in the aliphatic chain and in which a hydrogen at position 4 has been replaced by a hydroxy group.	2.21	1	4-hydroxynon-2-enal; 4-hydroxynonenal
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	2.21	1	cysteinium	fundamental metabolite
aluminum oxide Aluminum Oxide: An oxide of aluminum, occurring in nature as various minerals such as bauxite, corundum, etc. It is used as an adsorbent, desiccating agent, and catalyst, and in the manufacture of dental cements and refractories.	1.97	1

Condition	Relationship Strength	Studies
Acute Confusional Senile Dementia [description not available]	2.46	2
Protein Aggregation, Pathological A biochemical phenomenon in which misfolded proteins aggregate either intra- or extracellularly. Triggered by factors such as MUTATION; POST-TRANSLATIONAL MODIFICATIONS, and environmental stress, it is generally associated with ALZHEIMER DISEASE; PARKINSON DISEASE; HUNTINGTON DISEASE; and TYPE 2 DIABETES MELLITUS.	2.25	1
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.46	2
Degenerative Diseases, Central Nervous System [description not available]	2.93	1
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	2.93	1
Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.	2.41	2
Idiopathic Parkinson Disease [description not available]	2	1
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	2	1

3,4-dihydroxyphenylglycolaldehyde

Description

Cross-References

Synonyms (17)

Roles (3)

Drug Classes (2)

Pathways (16)

Research

Studies (14)

Market Indicators

Research Demand Index: 12.31

Study Types